Key facts
- Pleco Therapeutics’s last known valuation is $25.2M (Sep 2022).
- It has raised $31.1M; the latest was Later Stage VC ($13.7M) in Mar 2025.
- Notable investors include Oost NL, Rijksdienst voor Ondernemend Nederland, Brabant Startup Fund, Hyloris Pharmaceuticals.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Pleco Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pleco Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pleco Therapeutics
Developer of therapies intended to treat cancer and improve the effectiveness of existing chemotherapy. The company aims to extend the life span and enhance the quality of life of patients through its novel therapies that dramatically increase the effectiveness of current cancer treatments and positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell, enabling clinicians to treat cancer and also its underlying cause.
- Sector
- Healthcare
- HQ
- Apeldoorn, Netherlands
- Founded
- 2018
- Employees
- 12
- Website
- plecotherapeutics.com/
- Ownership
- Privately Held (backing)
Pleco Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pleco Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pleco Therapeutics in its N-PORT filings yet. We sweep new filings monthly.